|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ICK |
Gene summary for ICK |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ICK | Gene ID | 22858 |
| Gene name | ciliogenesis associated kinase 1 | |
| Gene Alias | ECO | |
| Cytomap | 6p12.1 | |
| Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | A0A024RD59 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 22858 | ICK | LZE2D | Human | Esophagus | HGIN | 8.16e-03 | 4.22e-01 | 0.0642 |
| 22858 | ICK | LZE2T | Human | Esophagus | ESCC | 4.21e-05 | 1.13e+00 | 0.082 |
| 22858 | ICK | LZE4T | Human | Esophagus | ESCC | 3.24e-08 | 1.78e-01 | 0.0811 |
| 22858 | ICK | LZE5T | Human | Esophagus | ESCC | 1.81e-03 | 4.51e-01 | 0.0514 |
| 22858 | ICK | LZE7T | Human | Esophagus | ESCC | 4.11e-11 | 6.09e-01 | 0.0667 |
| 22858 | ICK | LZE8T | Human | Esophagus | ESCC | 5.97e-04 | 6.92e-02 | 0.067 |
| 22858 | ICK | LZE20T | Human | Esophagus | ESCC | 5.26e-05 | 2.78e-01 | 0.0662 |
| 22858 | ICK | LZE24T | Human | Esophagus | ESCC | 2.22e-16 | 4.97e-01 | 0.0596 |
| 22858 | ICK | LZE21T | Human | Esophagus | ESCC | 3.36e-07 | 3.86e-01 | 0.0655 |
| 22858 | ICK | P1T-E | Human | Esophagus | ESCC | 2.28e-07 | 4.15e-01 | 0.0875 |
| 22858 | ICK | P2T-E | Human | Esophagus | ESCC | 1.43e-15 | 3.08e-01 | 0.1177 |
| 22858 | ICK | P4T-E | Human | Esophagus | ESCC | 6.71e-31 | 7.56e-01 | 0.1323 |
| 22858 | ICK | P5T-E | Human | Esophagus | ESCC | 2.98e-03 | 7.61e-02 | 0.1327 |
| 22858 | ICK | P8T-E | Human | Esophagus | ESCC | 9.58e-14 | 2.75e-01 | 0.0889 |
| 22858 | ICK | P9T-E | Human | Esophagus | ESCC | 9.95e-20 | 4.63e-01 | 0.1131 |
| 22858 | ICK | P10T-E | Human | Esophagus | ESCC | 7.51e-16 | 3.66e-01 | 0.116 |
| 22858 | ICK | P11T-E | Human | Esophagus | ESCC | 2.23e-04 | 1.88e-01 | 0.1426 |
| 22858 | ICK | P12T-E | Human | Esophagus | ESCC | 8.75e-31 | 8.12e-01 | 0.1122 |
| 22858 | ICK | P15T-E | Human | Esophagus | ESCC | 1.10e-14 | 2.92e-01 | 0.1149 |
| 22858 | ICK | P16T-E | Human | Esophagus | ESCC | 8.31e-19 | 4.04e-01 | 0.1153 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00488638 | Esophagus | ESCC | stem cell differentiation | 122/8552 | 206/18723 | 5.95e-05 | 4.59e-04 | 122 |
| GO:0030041110 | Esophagus | ESCC | actin filament polymerization | 114/8552 | 191/18723 | 6.46e-05 | 4.92e-04 | 114 |
| GO:000806419 | Esophagus | ESCC | regulation of actin polymerization or depolymerization | 112/8552 | 188/18723 | 8.31e-05 | 6.06e-04 | 112 |
| GO:003083218 | Esophagus | ESCC | regulation of actin filament length | 112/8552 | 189/18723 | 1.13e-04 | 7.85e-04 | 112 |
| GO:003083320 | Esophagus | ESCC | regulation of actin filament polymerization | 103/8552 | 172/18723 | 1.19e-04 | 8.15e-04 | 103 |
| GO:00100016 | Esophagus | ESCC | glial cell differentiation | 129/8552 | 225/18723 | 2.73e-04 | 1.65e-03 | 129 |
| GO:00600714 | Esophagus | ESCC | Wnt signaling pathway, planar cell polarity pathway | 36/8552 | 52/18723 | 5.05e-04 | 2.79e-03 | 36 |
| GO:200073614 | Esophagus | ESCC | regulation of stem cell differentiation | 39/8552 | 58/18723 | 7.43e-04 | 3.86e-03 | 39 |
| GO:003431415 | Esophagus | ESCC | Arp2/3 complex-mediated actin nucleation | 28/8552 | 39/18723 | 8.57e-04 | 4.40e-03 | 28 |
| GO:00901753 | Esophagus | ESCC | regulation of establishment of planar polarity | 37/8552 | 56/18723 | 1.65e-03 | 7.65e-03 | 37 |
| GO:004825916 | Esophagus | ESCC | regulation of receptor-mediated endocytosis | 66/8552 | 110/18723 | 1.72e-03 | 7.96e-03 | 66 |
| GO:00301788 | Esophagus | ESCC | negative regulation of Wnt signaling pathway | 97/8552 | 170/18723 | 1.81e-03 | 8.31e-03 | 97 |
| GO:00454454 | Esophagus | ESCC | myoblast differentiation | 52/8552 | 84/18723 | 1.98e-03 | 8.90e-03 | 52 |
| GO:00017361 | Esophagus | ESCC | establishment of planar polarity | 45/8552 | 72/18723 | 2.97e-03 | 1.24e-02 | 45 |
| GO:00071641 | Esophagus | ESCC | establishment of tissue polarity | 45/8552 | 72/18723 | 2.97e-03 | 1.24e-02 | 45 |
| GO:00355671 | Esophagus | ESCC | non-canonical Wnt signaling pathway | 45/8552 | 72/18723 | 2.97e-03 | 1.24e-02 | 45 |
| GO:000930617 | Esophagus | ESCC | protein secretion | 190/8552 | 359/18723 | 3.22e-03 | 1.34e-02 | 190 |
| GO:004826010 | Esophagus | ESCC | positive regulation of receptor-mediated endocytosis | 34/8552 | 52/18723 | 3.26e-03 | 1.35e-02 | 34 |
| GO:003559217 | Esophagus | ESCC | establishment of protein localization to extracellular region | 190/8552 | 360/18723 | 3.77e-03 | 1.53e-02 | 190 |
| GO:00343156 | Esophagus | ESCC | regulation of Arp2/3 complex-mediated actin nucleation | 16/8552 | 21/18723 | 4.47e-03 | 1.76e-02 | 16 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ICK | SNV | Missense_Mutation | novel | c.1348G>C | p.Glu450Gln | p.E450Q | Q9UPZ9 | protein_coding | tolerated(0.15) | benign(0.015) | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response |
| ICK | SNV | Missense_Mutation | novel | c.1126N>C | p.Ser376Pro | p.S376P | Q9UPZ9 | protein_coding | tolerated(0.14) | benign(0.009) | TCGA-A2-A1G4-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | adriamycin | SD |
| ICK | SNV | Missense_Mutation | novel | c.1126T>C | p.Ser376Pro | p.S376P | Q9UPZ9 | protein_coding | tolerated(0.14) | benign(0.009) | TCGA-A8-A06R-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | CR |
| ICK | SNV | Missense_Mutation | c.613G>A | p.Glu205Lys | p.E205K | Q9UPZ9 | protein_coding | deleterious(0) | probably_damaging(0.969) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| ICK | SNV | Missense_Mutation | rs561765544 | c.995G>A | p.Arg332Gln | p.R332Q | Q9UPZ9 | protein_coding | tolerated(0.52) | benign(0.007) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ICK | SNV | Missense_Mutation | c.932N>T | p.Ala311Val | p.A311V | Q9UPZ9 | protein_coding | tolerated(0.31) | benign(0.001) | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ICK | SNV | Missense_Mutation | novel | c.1126N>C | p.Ser376Pro | p.S376P | Q9UPZ9 | protein_coding | tolerated(0.14) | benign(0.009) | TCGA-BH-A1FH-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| ICK | SNV | Missense_Mutation | novel | c.1126T>C | p.Ser376Pro | p.S376P | Q9UPZ9 | protein_coding | tolerated(0.14) | benign(0.009) | TCGA-C8-A273-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
| ICK | SNV | Missense_Mutation | novel | c.1126N>C | p.Ser376Pro | p.S376P | Q9UPZ9 | protein_coding | tolerated(0.14) | benign(0.009) | TCGA-D8-A1JT-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| ICK | SNV | Missense_Mutation | novel | c.1126N>C | p.Ser376Pro | p.S376P | Q9UPZ9 | protein_coding | tolerated(0.14) | benign(0.009) | TCGA-D8-A1XG-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |